Phase I clinical trial - Pédiatrie Tumeurs solides
AMG 20110261
Pédiatrie Tumeurs solides
Essai clinique fermé
Public cible
Enfant
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non-central Nervous System Tumors That are Amenable to Direct Injection.
Description de l'essai
To determine the safety and tolerability of talimogene laherparepvec, as assessed by incidence of dose-limiting toxicities (DLT), in pediatric subjects with advanced;non-central nervous system (CNS) tumors that are amenable to direct injection.
Liens utiles
ISABELLE AERTS
Investigateur principal